A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)

Experimental and Molecular Pathology

Volumn 99, Issue 1, 2015, Pages 16-18

  Marcé, Silvia ^a   Cortés, Montserrat ^b   Zamora, Lurdes ^a   Cabezón, Marta ^a   Grau, Javier ^a   Millá, Fuensanta ^a   Feliu, Evarist ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

BCR ABL1; CML; Insertion; Mutation; Resistance; TKI

Indexed keywords

ABL1 KINASE; COMPLEMENTARY DNA; DASATINIB; IMATINIB; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; MESSENGER RNA; NUCLEOTIDE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABL1 GENE; ADULT; ANEMIA; ARTICLE; BCR ABL1 GENE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER RESISTANCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA EXTRACTION; DRUG TREATMENT FAILURE; FEMALE; FUSION GENE; GENE INSERTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIA; LEUKOCYTOSIS; MOLECULAR CLONING; MUTATIONAL ANALYSIS; ONCOGENE; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; STOP CODON; CHEMISTRY; DNA SEQUENCE; DRUG RESISTANCE; EXON; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADULT; BASE SEQUENCE; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NUCLEOTIDES; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; THIAZOLES;

EID: 84929146900     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.04.007     Document Type: Article

References (14)

1. Apperley J. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
2. Chu S.C., Tang J.L., Li C.C. Dasatinib in chronic myelogenous leukemia. N. Engl. J. Med. 2006, 355(10):1062-1063.
3. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cavé H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia 2003, 2318-2357.
4. Laudadio J., Deninger M.W.N., Mauro M.J., Druker B.J., Press R.D. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J. Mol. Diagn. 2008, 10(2):177-180.
5. Lee T.S., Ma W., Zhang X., Giles F., Cortes J., Katarjian H., Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol. Cancer Ther. 2008, 7(12):3834-3841.
6. Ma W., Kantarjian H., Yeh C.H., Zhang Z.J., Cortes J., Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009, 121(1):27-31.
7. Mahadeo K.M., Cole P.D. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS. Blood 2010, 115(18):3852.
8. Marcé S., Zamora L., Cabezón M., Xicoy B., Boqué C., Fernández C., Grau J., Navarro J.T., Fernández de Sevilla A., Ribera J.M., Feliu E., Millá F. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Med. Clin. 2013, 141(3):95-99.
9. Nadarajan V.S., Ang C.H., Syed-Sultan M.K., Bee P.C. Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294. Ann. Hematol. 2012, 91(1):125-127.
10. O'Hare T., Zabriskie M.S., Eide C.A., Agarwal A., Adrian L.T., You H., Corbin A.S., Yang F., Press R.D., Rivera V.M., Toplin J., Wong S., Deininger M.W., Druker B.J. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 2011, 118:5250-5254.
11. Sakai K., Ishikawa Y., Mori Y., Kobayashi M., Iriyama C., Ozawa Y., Suzuki T., Minami Y., Ishikawa K., Kaneda N., Naoe T., Kiyoi H. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int. J. Hematol. 2011, 93(2):237-242.
12. Shaffer L.G., McGowan-Jordan J., Schmid M. ISCN 2013. An international system for human cytogenetic nomenclature (2013). Recommendations for international standing committee on human cytogenetic nomenclature. Cytogenet. Genome Res. 2013.
13. Sigl M., Spoerl S., Schnittger S., Meissner J., Rummelt C., Peschel C., Duyster J., Ho A.D., von Bubnoff N. Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation. Blood Cancer J. 2013, 3:e104.
14. Swerdlow S.H. Organización Mundial de la Salud and Asociación Internacional de Investigación sobre el Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, International Agency for Research on Cancer, Lyon. 4th ed.